Pharming Group N.V. (PHAR)
NASDAQ: PHAR
· Real-Time Price · USD
10.41
-0.19 (-1.79%)
At close: May 23, 2025, 3:34 PM
10.55
1.34%
After-hours: May 23, 2025, 04:04 PM EDT
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2020 |
|---|---|---|---|
| United States Revenue | 287.15M | 239.11M | 177.39M |
| United States Revenue Growth | +20.09% | +34.79% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Aug 5, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 57.06M | 48.58M | 43.98M | 48.45M | 45.23M | 54.79M | 35.82M | 44.89M | 37.09M | 46.55M | 32.4M | 27.95M | 24.93M | 25.89M | 21.1M | 21.83M | 21.33M | 16.22M | 18.99M | 16.36M | 18.4M | 21.08M | 13.42M | 17.32M | 14.08M | 13.6M | 14.48M | 12.26M | 13.15M | 17.13M | 11.99M | 10.1M | 5.65M | 3.55M | 1.58M | 1.63M | 1.31M | 1.21M | 1.36M | 1.5M | 1.2M |
| Selling, General, and Administrative Revenue Growth | +17.44% | +10.47% | -9.24% | +7.13% | -17.45% | +52.95% | -20.19% | +21.03% | -20.33% | +43.71% | +15.92% | +12.12% | -3.73% | +22.68% | -3.32% | +2.32% | +31.55% | -14.61% | +16.06% | -11.07% | -12.72% | +57.13% | -22.56% | +23.05% | +3.50% | -6.03% | +18.09% | -6.80% | -23.21% | +42.87% | +18.67% | +78.82% | +59.05% | +125.08% | -3.31% | +24.35% | +8.19% | -10.66% | -9.75% | +24.93% | n/a |
| Research and Development Revenue | 21.14M | 22.14M | 20.72M | 21.58M | 18.48M | 11.7M | 20.65M | 20.89M | 15.62M | 10.89M | 12.34M | 14.43M | 14.86M | 17.03M | 25.18M | 13.51M | 10.38M | 13.51M | 9.97M | 9.14M | 8.84M | 5.82M | 9.04M | 10.96M | 5.96M | 12.62M | 6.52M | 6.82M | 7.07M | 7.04M | 4.87M | 5.46M | 5.01M | 3.75M | 4.61M | 3.63M | 4.19M | 3.9M | 4.24M | 4.43M | 2.94M |
| Research and Development Revenue Growth | -4.51% | +6.86% | -3.98% | +16.79% | +57.99% | -43.35% | -1.16% | +33.73% | +43.41% | -11.76% | -14.48% | -2.89% | -12.73% | -32.36% | +86.45% | +30.13% | -23.18% | +35.51% | +9.05% | +3.39% | +51.97% | -35.66% | -17.47% | +83.93% | -52.81% | +93.49% | -4.28% | -3.63% | +0.49% | +44.47% | -10.78% | +8.98% | +33.51% | -18.62% | +27.01% | -13.29% | +7.47% | -8.17% | -4.14% | +50.72% | n/a |
| Sales and Marketing Revenue | 34.57M | -84.73M | 28.69M | 32.93M | 30.25M | -79.32M | 25.12M | 33.91M | 27.11M | 28.98M | 20.37M | 19.25M | 17.2M | 13.5M | 14.17M | 13.91M | 14.39M | 17.85M | 12.97M | 12.03M | 12.7M | 11.69M | 9.4M | 12.88M | 10.74M | 9.29M | 10.87M | 9.23M | 10.12M | 15.02M | 9.94M | 8.56M | 4.18M | 2.17M | 356.86K | 419.24K | 245.93K | 210.68K | 279.03K | 445.28K | 251.24K |
| Sales and Marketing Revenue Growth | -140.80% | -395.36% | -12.88% | +8.86% | -138.14% | -415.72% | -25.90% | +25.08% | -6.48% | +42.29% | +5.81% | +11.95% | +27.37% | -4.74% | +1.86% | -3.29% | -19.38% | +37.61% | +7.79% | -5.26% | +8.66% | +24.34% | -27.00% | +19.85% | +15.64% | -14.50% | +17.69% | -8.71% | -32.64% | +51.16% | +16.01% | +104.92% | +92.61% | +508.05% | -14.88% | +70.47% | +16.73% | -24.50% | -37.34% | +77.23% | n/a |